Opendata, web and dolomites

TETHIS-SBS-CTC

TETHIS-SBS-CTC: An innovative diagnostic testing platform to identify and characterize circulating tumour cells (CTCs) in blood samples.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TETHIS-SBS-CTC project word cloud

Explore the words cloud of the TETHIS-SBS-CTC project. It provides you a very rough idea of what is the project "TETHIS-SBS-CTC" about.

blood    time    capture    drug    cells    capability    biosurface    immobilize    posing    once    therapy    biopsy    sectors    settings    biotech    feasibility    cancer    sbs    finalise    diagnostic    58    profits    standpoint    realization    oncology    combination    environment       characterization    death    proteomic    alternatives    70    led    market    biology    encloses    15    expecting    metastatic    rate    huge    expertise    accounting    clinical    pilot    liquid    cellular    diagnosed    culminating    financial    run    tumour    healthcare    methodology    adequately    driving    stage    molecular    total    tethis    reflection    enrichment    smart    aggression    deaths    marker    hire    secure    ctcs    monitoring    decades    earlier    roi    commercial    diagnostics    discovery    pharma    worldwide    million    preparation    gain    finished    validated    detection    helps    nanotechnology    people    platform    creates    causes    perfect    chance    turn    cure    conceived    circulating   

Project "TETHIS-SBS-CTC" data sheet

The following table provides information about the project.

Coordinator
TETHIS SPA 

Organization address
address: VIA DE GRASSI GIOVANNINO 11
city: MILANO
postcode: 20123
website: www.tethis-lab.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.tethis-lab.com/liquid-biopsy/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TETHIS SPA IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Cancer is one of the most important causes of death worldwide, accounting for 8.8 million deaths. The rate of new cases is expected to rise by 70% in the next 2 decades, posing a huge challenge for the healthcare system. If diagnosed early and treated adequately, many cases would have a high chance of cure. This realization is driving the growth in the cancer diagnostics market. The detection and analysis of Circulating Tumour Cells (CTCs) encloses a huge potential for real-time monitoring of cancer cases. CTCs are considered a “diagnostic tumour marker” since they are the reflection of a metastatic aggression. We at TETHIS have developed a new diagnostic platform to characterize CTCs from liquid biopsy (i.e. blood). The combination of our expertise in nanotechnology and strong biology knowledge have led to the development of a Smart BioSurface (SBS) that creates a perfect environment to immobilize CTCs using a total capture approach. Compared to the state-of-the-art alternatives, our methodology does not require pre-enrichment or selection. Having validated this technology for cancer diagnostics at the pilot stage, this project is conceived to finalise the development and market preparation of this technology, culminating in a diagnostic platform for cellular, proteomic and molecular characterization of CTCs. The platform will have key applications, including diagnostics and monitoring in clinical settings, and drug discovery & therapy development in the pharma/biotech sectors. The Phase 1 of this project is dedicated to run a Feasibility Study that helps us evaluate the project from a technical, commercial and financial standpoint. Once the project is finished, we expect our platform to improve the diagnostic capability in the oncology sector, enabling earlier detection and better management. In turn, it will secure the growth for TETHIS, expecting to gain over €10 million in profits, hire 15 new people and reach a ROI of €2.58 from this project after 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TETHIS-SBS-CTC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TETHIS-SBS-CTC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More